
    
      Conducted in Lima Peru, 20 HIV-1 and HSV-2 seropositive women with CD4 counts greater than
      200 and on no antiretroviral therapy were randomly assigned to receive valacyclovir 500 mg
      bid or placebo for the first 8 weeks of the study. After these 8 weeks, a 2-week washout
      period followed, which was then followed by the alternative regimen for 8 weeks.
    
  